$450,000 of convertible debt being eliminated

• Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials

• Conversion of all reported outstanding preferred shares and debt into equity occurred as of the date of the IPO and is not reflected in the reported financials

• After IPO and preferred shares and debt conversion share issuances, there are 20.85 million common shares outstanding, with 1.86 million common shares available to be traded

• Underwriter lockups limit potential for deposit or trading of remaining 18.99 million common shares

• As of the date of the IPO, Company had no debt, cash runway for lead program OST-HER2 into mid-2025

Net Loss and Earnings per Diluted Share of $10.6 million and $17.48

Adjusted EBITDA was a $2.9 million loss, a $2.8 million improvement versus second quarter of 2023

The Company expects to generate between $2.0 million and $2.5 million in revenue in the third quarter of 2024

Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System

Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited

Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time

Revealia™, the world’s most convenient cancer screening test, to launch in 2024

Company provides nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers such as Medicare, Select Health, Medicaid, and Blue Cross Blue Shield

Reimbursement from insurance payors increased 163.7% sequentially and is expected to increase as a percentage of total revenue going forward

Reimbursements from insurance payors totaled $126,325 in first half of 2024 as compared to $0 during the first half of 2023

Companies share joint commitment to leveraging technology for STEM education

Accessible education on cutting-edge science and technology represents critical step toward closing workforce readiness gap

 Anne Milgram DEA Administrator Continues to Hinder Marijuana Research and Drug Development 

The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million

Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results

Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System

Strategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally

Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devices

All-stock licensing structure aligns the licensor's long-term interest with Ainos shareholders'

• European revenues increased 20% compared to same period last year

• Gross margin of 39% compared to 35% in same period last year

• Net loss improved 19% compared to same period last year

Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review

FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested

"Pioneering Fully Automated AI Customer Acquisition"

- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients

- Dermata continues discussions with potential botulinum toxin partners for DMT410

- Raised $2.3 million in net proceeds from financing completed in 2Q 2024